Full Press Release Details
BridgeBio Pharma Shares Positive Results Of Single-arm Phase 3 Study Of Acoramidis In Japanese Patients With ATTR-CM.
BBIO
BridgeBio Pharma Shares Positive Results Of Single-arm Phase 3 Study Of Acoramidis In Japanese Patients With ATTR-CM
Key Takeaway: BridgeBio Pharma Shares Positive Results Of Single-arm Phase 3 Study Of Acoramidis In Japanese Patients With ATTR-CM
Price reaction · baseline $33.31 (2024-02-01 close) · hit after-hours · 3 other BBIO headline(s) in the window, move may be shared
day 0 close · peak
+1.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis